http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2129282-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ae95e7759e7ecd9a4ab7f46795c1ce3 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-70 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-335 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate | 1994-08-02^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89a647a82f024f612c71feaf6926f642 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1721d1355572cfcafd1388d340162697 |
| publicationDate | 1995-03-30^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2129282-A1 |
| titleOfInvention | Method for the treatment of neoplastic disease utilizing taxol and tiazofurin |
| abstract | ABSTRACT A method of treating neoplastic cells using a combination of taxol and tiazofurin. Preferably, the taxol is administered in a dosage of approximately 110 mg/m2 to approximately 250 mg/m2 on a single day, followed by 31 days of rest, and the tiazofurin is administered in a dosage of approximately 1,800 to 4,400 mg/m2 over a period of about ten days, followed by 21 days of rest, and the taxol and tiazofurin administration cycles are in phase with each other. |
| priorityDate | 1993-09-29^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Showing number of triples: 1 to 183 of 183.